Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26FX4D1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,339
Award facts
- Contract value 100% obligated
- $38,339.01 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $38,339.01 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pharmaceutical products. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and was executed on January 7, 2026, with an ultimate completion date of January 8, 2026. The delivery location is Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc., which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031, serving as the primary vehicle for pharmaceutical and medical supply distribution to military healthcare programs globally.
AmerisourceBergen's federal contract portfolio demonstrates extensive capability in delivering specialty pharmaceuticals across multiple therapeutic domains to military treatment facilities and veteran healthcare systems. The company's role as a prime pharmaceutical vendor reflects its critical position within the federal medical supply chain, particularly for medications supporting Defense Health Agency operations and U.S. Coast Guard healthcare requirements. Repatha, a cholesterol-lowering medication used in cardiovascular disease management, represents the type of specialty pharmaceutical products the company routinely supplies through its DLA contract vehicle, which encompasses brand-name drugs, generic medications, vaccines, and specialized medical devices.
Quick answers
Who was awarded contract SPE2DR26FX4D1?
SPE2DR26FX4D1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FX4D1 worth?
The government has obligated $38,339 on SPE2DR26FX4D1.
Is contract SPE2DR26FX4D1 an order under another contract?
Yes. SPE2DR26FX4D1 is a delivery order under SPE2DR25D2218, an indefinite delivery contract.
Was contract SPE2DR26FX4D1 competed?
The extent of competition for SPE2DR26FX4D1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award